Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside for SMDS
NCT06280482Phase 1Recruiting
- Sponsor
- UTHealth Houston
- Start
- Mar 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide riboside in multisystemic smooth muscle dysfunction syndrome (MSMDS), sponsored by UTHealth Houston. Primary endpoints: Change in systolic blood pressure at 8 weeks, Change in cerebral oxygenation and perfusion at 8 weeks and 5 more. Started Mar 2024; status: recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
multisystemic smooth muscle dysfunction syndrome (MSMDS)
Beyond the preview
Go deeper on NCT06280482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280482.